Blog
Pfizer’s $43bn Seagen Deal Boosts Cancer Portfolio
📢 Pfizer seals the deal with Seagen, bolstering its presence in the cancer drug market. 💪✨ $43bn acquisition expands Pfizer's cancer treatment portfolio.
AstraZeneca Boosts Vaccine Portfolio with $11bn Icosavax Deal
🔍 AstraZeneca acquires Icosavax for $1.1bn, expanding its respiratory vaccine pipeline and strengthening its global biotech position. 🌡️💉🌍
Vandria SA Raises CHF18m for Neurodegenerative Disease Treatment
📣 Vandria SA 🏢 secures CHF18m 💰 in Series A financing 💼 to develop VNA-318, a potential treatment for neurodegenerative diseases.
Antabio SAS Raises €25m for Breakthrough Antibiotic Development
📢 Antibiotics specialist Antabio SAS has secured €25m in Series B financing to support clinical development of next-gen antibacterial combination. 🧪🔬
Revolutionary Coffee Production: No Beans Needed!
📢 Scientists led by Heiko Rischer from VTT have published a proof of concept for cell-based coffee production. 🍃☕️🌱
Germany’s Block on NGT Deregulation Sparks Controversy
📅 At the EU Council, ministers failed to adopt new regulation on genomic techniques. 🌱 Spain pushed, ❌ Germany opposed. 🌾 Debate: NGT breeds vs organic breeds and patent bans.
Carthera Raises €42m to Launch Clinical Trials
📢 Sorbonne University spin-out Carthera SA has closed its Series B funding round at €42m to launch clinical trials. The funds will be used to launch a registrational trial of its ultrasound-based medical device SonoCloud to treat recurrent glioblastoma. Carthera also plans to expand its pipeline in neurodegenerative diseases.
UK Unveils £2bn Plan for Biological Breakthroughs
🇬🇧🔬 The UK unveils a £2bn plan for engineering biology: cellular agriculture, genomic techniques, medicinal advancements, and sustainable fuel.
Massive Lyme Vaccine Trial Concludes with Promising Results
📢 Pfizer and Valneva's Phase 3 VALOR trial for Lyme vaccine, VLA15, completes enrollment with over 9,000 participants. 🌍🩺🔬😷
Game-Changing Breakthrough: Targeting Prostate Cancer’s Weakness
🔬 An international research team has discovered a potential method to target and inhibit the androgen receptor in aggressive prostate cancer by exploiting protein droplets called condensates. 💡 This research lays the groundwork for the development of new treatments targeting these challenging proteins. 🧪 Further research is needed to translate these findings into viable therapies. Nuage Therapeutics is pursuing the development of new treatments based on these discoveries.
